Responses
Late-Breaking Abstracts
Clinical Trial Completed
1518 T-cell inducing oncolytic virus (igrelimogene litadenorepvec; TILT-123) shows safety, anti-tumor activity and induction of immune responses in advanced solid tumor patients (full report on TUNIMO)
Compose a Response to This Article
Other responses
No responses have been published for this article.
